BTG PLC | Income Statement

Fiscal year is April-March. All values GBP Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
290,500.00
367,800.00
447,500.00
570,500.00
620,500.00
Cost of Goods Sold (COGS) incl. D&A
122,700.00
149,700.00
175,800.00
221,900.00
229,900.00
Gross Income
167,800.00
218,100.00
271,700.00
348,600.00
390,600.00
SG&A Expense
125,300.00
186,500.00
218,300.00
266,400.00
280,400.00
EBIT
42,500.00
31,600.00
53,400.00
82,200.00
110,200.00
Unusual Expense
5,200.00
10,900.00
600.00
37,000.00
185,700.00
Non Operating Income/Expense
4,200.00
5,900.00
3,300.00
13,900.00
4,400.00
Pretax Income
33,300.00
26,700.00
57,500.00
31,600.00
70,600.00
Income Tax
9,000.00
6,900.00
3,000.00
2,000.00
83,300.00
Consolidated Net Income
24,300.00
33,600.00
60,500.00
33,600.00
12,700.00
Net Income
24,300.00
33,600.00
60,500.00
33,600.00
15,000.00
Net Income After Extraordinaries
24,300.00
33,600.00
60,500.00
33,600.00
15,000.00
Net Income Available to Common
24,300.00
33,600.00
60,500.00
33,600.00
15,000.00
EPS (Basic)
0.07
0.09
0.16
0.09
0.04
Basic Shares Outstanding
355,200.00
367,900.00
382,600.00
384,400.00
386,100.00
EPS (Diluted)
0.07
0.09
0.16
0.09
0.04
Diluted Shares Outstanding
359,800.00
373,300.00
388,300.00
390,000.00
389,200.00
EBITDA
70,200.00
66,600.00
97,700.00
135,000.00
165,800.00
Non-Operating Interest Income
200.00
100.00
200.00
300.00
500.00
Minority Interest Expense
-
-
-
-
2,300.00

About BTG

View Profile
Address
5 Fleet Place
London London & South East EC4M 7RD
United Kingdom
Employees -
Website http://btgplc.com
Updated 07/08/2019
BTG Plc is a global healthcare company, which focuses on interventional medicine that can help physicians to treat patients through minimally invasive procedures. It operates through the following business segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment provides therapies for cancer, sever emphysema, and vascular conditions such as severe blood clots and varicose veins.